Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease
Objective: To compare the gut microbiota in patients with Parkinson’s disease (PD) and healthy controls and predict the functional pathways associated with these differences. Background:…Altered gut microbiota composition and metabolism in Parkinson’s disease
Objective: To define changes in gut microbiota composition and metabolism to enable identification of novel therapeutic targets and strategies for disease modification. Background: Multiple cohort…Exploring the Influence of Gastrointestinal Symptoms on Non-Motor Fluctuations in Parkinson’s Disease: Insights from the ReMePark-2, a Mexican Cohort
Objective: To determine the impact of gastrointestinal symptoms on NMF in PD among Mexican individuals living with PD (PwP). Background: The growing interest in the…Risk of Parkinson’s Disease due to Helicobacter Pylori and High Salt Consumption
Objective: The association between excessive salt consumption, susceptibility to H. pylori infection and risk of Parkinson's disease will be analyzed through scientific studies. Background: The…Non-motor Symptoms Progression in Parkinson´s Disease. A 4-year Follow-up Study.
Objective: The aim of the present study was to know how Non-motor Symptoms (NMS) change over time in patients with Parkinson´s disease (PD) comparing to…The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease
Objective: The aim of this study is to explore the function and mechanism of RNA m6A modification in gut-derived inflammation of Parkinson's disease (PD). Background:…Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia
Objective: Describe a PD patient with obsessive-compulsive disorder (OCD) and paranoid symptoms in whom treatment with LCIG was started in the ICU due to severe…Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD is achieved. Background: Gastroparesis (GP) is one…Gut microbiota dysbiosis in Parkinson’s disease patients: a potential biomarker of disease severity and progression?
Objective: To investigate gut microbiota alterations in Parkinson's disease (PD) along disease progression. Background: Gut microbiota dysbiosis is considered a hallmark in PD1. However, it is…Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial
Objective: To evaluate the effect of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on gut microbiota composition, motor and non-motor symptoms…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »